There were no differences in mental health outcomes between montelukast and long-acting beta-agonists. Psychiatric events rose over time, likely due to increased screening, diagnoses and awareness.

"Montelukast can now be added to the list of ... which "might be significant for a proposed antiviral mechanism of action," ...

Use of montelukast not associated with risk of neuropsychiatric adverse events among children suggests a new study published in the JAMA.Spontaneous reports have indicated that ...